202 related articles for article (PubMed ID: 34330313)
1. Molecular features and vulnerabilities of recurrent chordomas.
Seeling C; Lechel A; Svinarenko M; Möller P; Barth TFE; Mellert K
J Exp Clin Cancer Res; 2021 Jul; 40(1):244. PubMed ID: 34330313
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
3. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
Jäger D; Barth TFE; Brüderlein S; Scheuerle A; Rinner B; von Witzleben A; Lechel A; Meyer P; Mayer-Steinacker R; Baer AV; Schultheiss M; Wirtz CR; Möller P; Mellert K
Sci Rep; 2017 May; 7(1):2032. PubMed ID: 28515451
[TBL] [Abstract][Full Text] [Related]
4. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.
Alholle A; Brini AT; Bauer J; Gharanei S; Niada S; Slater A; Gentle D; Maher ER; Jeys L; Grimer R; Sumathi VP; Latif F
Epigenetics; 2015; 10(3):213-20. PubMed ID: 25621392
[TBL] [Abstract][Full Text] [Related]
6. The potential function of microRNA in chordomas.
Gulluoglu S; Tuysuz EC; Kuskucu A; Ture U; Atalay B; Sahin F; Bayrak OF
Gene; 2016 Jul; 585(1):76-83. PubMed ID: 27016303
[TBL] [Abstract][Full Text] [Related]
7. Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma.
Shen LY; Zhou T; Du YB; Shi Q; Chen KN
Cancer Sci; 2019 May; 110(5):1735-1745. PubMed ID: 30844117
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.
Scheil S; Brüderlein S; Liehr T; Starke H; Herms J; Schulte M; Möller P
Genes Chromosomes Cancer; 2001 Nov; 32(3):203-11. PubMed ID: 11579460
[TBL] [Abstract][Full Text] [Related]
9. Differential proteomic profiling of primary and recurrent chordomas.
Chen S; Xu W; Jiao J; Jiang D; Liu J; Chen T; Wan Z; Xu L; Zhou Z; Xiao J
Oncol Rep; 2015 May; 33(5):2207-18. PubMed ID: 25738923
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma.
Kim JY; Lee J; Koh JS; Park MJ; Chang UK
J Neurosurg Spine; 2016 Nov; 25(5):626-635. PubMed ID: 27314550
[TBL] [Abstract][Full Text] [Related]
11. U-CH17P, -M and -S, a new cell culture system for tumor diversity and progression in chordoma.
Jäger D; Lechel A; Tharehalli U; Seeling C; Möller P; Barth TFE; Mellert K
Int J Cancer; 2018 Apr; 142(7):1369-1378. PubMed ID: 29148152
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma.
Zhu GG; Ramirez D; Chen W; Lu C; Wang L; Frosina D; Jungbluth A; Ntiamoah P; Nafa K; Boland PJ; Hameed MR
Hum Pathol; 2020 Oct; 104():73-83. PubMed ID: 32795465
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models.
Locquet MA; Dechaume AL; Berchard P; Abbes L; Pissaloux D; Tirode F; Ramos I; Bedoucha J; Valantin J; Karanian M; Perret R; Gille O; Blay JY; Dutour A
Cells; 2021 Feb; 10(2):. PubMed ID: 33672032
[TBL] [Abstract][Full Text] [Related]
14. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
15. Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma.
Gulluoglu S; Sahin M; Tuysuz EC; Yaltirik CK; Kuskucu A; Ozkan F; Sahin F; Ture U; Bayrak OF
Oncol Res; 2017 Aug; 25(7):1177-1188. PubMed ID: 28247842
[TBL] [Abstract][Full Text] [Related]
16. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of chordoma.
Scheil-Bertram S; Kappler R; von Baer A; Hartwig E; Sarkar M; Serra M; Brüderlein S; Westhoff B; Melzner I; Bassaly B; Herms J; Hugo HH; Schulte M; Möller P
Int J Oncol; 2014 Apr; 44(4):1041-55. PubMed ID: 24452533
[TBL] [Abstract][Full Text] [Related]
18. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
19. SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression.
Walhart TA; Vacca B; Hepperla AJ; Hamad SH; Petrongelli J; Wang Y; McKean EL; Moksa M; Cao Q; Yip S; Hirst M; Weissman BE
Am J Pathol; 2023 Apr; 193(4):456-473. PubMed ID: 36657718
[TBL] [Abstract][Full Text] [Related]
20. Impact of CDK Inhibitors on
Bette S; Haase L; Nell J; Grieser T; von Baer A; Schultheiss M; Marienfeld R; Möller P; Barth TFE; Mellert K
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
